FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to new antisense conjugates; it can be used in medicine. The invention allows for the production of a conjugate for inhibition of expression of a hepatitis B virus gene, containing small interfering RNA (siRNA), which is modified nucleotide aimed at a target gene, and targeting ligand, which is capable of binding to asialoglycoprotein receptors (ASGP-R) on the surface of mammalian hepatocytes.
EFFECT: invention can be used in medical practice as a drug in the treatment of pathological conditions or diseases caused by an infection of a hepatitis B virus (HBV), for example chronic liver diseases, hepatitis, liver fibrosis, and proliferative liver diseases.
25 cl, 6 ex, 4 tbl, 28 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, METHOD OF PRODUCTION AND USE | 2020 |
|
RU2819689C2 |
| NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE, METHOD OF PRODUCTION AND USE | 2020 |
|
RU2816898C2 |
| CONJUGATES AND THEIR OBTAINING AND APPLICATION | 2018 |
|
RU2795400C2 |
| NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN CELL | 2018 |
|
RU2822093C1 |
| MIRNA STRUCTURES WITH HIGH ACTIVITY AND REDUCED EXPOSURE OUTSIDE THE TARGET | 2016 |
|
RU2788030C2 |
| TRIALKYL CATIONIC LIPIDS AND METHODS FOR USING THEM | 2013 |
|
RU2718053C2 |
| COMBINED DRUG WITH ANTIVIRAL EFFECT AGAINST NEW SARS-COV-2 CORONAVIRUS | 2021 |
|
RU2746362C1 |
| COMPOSITION OF DELIVERY SYSTEM BASED ON CONJUGATE FOR RNA-INTERFERENCE POLYNUCLEOTIDE DELIVERY TO LIVER CELL AND PROCESS FOR ITS PREPARATION | 2011 |
|
RU2623160C9 |
| LOW-MOLECULAR CONJUGATES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | 2011 |
|
RU2582235C2 |
| PHARMACEUTICAL COMPOSITIONS, KITS AND METHODS OF TREATING TUMORS | 2019 |
|
RU2810906C2 |
